Mark Makhinson, PharmD

Articles by Mark Makhinson, PharmD

4 experts in this video

Panelists discuss how recent clinical trials like ADmirable and DISCOVER intentionally enrolled patients with skin of color (Fitzpatrick types IV-VI), demonstrating similar efficacy and safety profiles for biologics across diverse racial populations, with more than 70% achieving a 75% or greater improvement in the Eczema Area and Severity Index (EASI-75).

4 experts in this video

Panelists discuss how health care providers need coordinated multidisciplinary care teams, visual resources like databases for eczema in skin of color, peer-to-peer educational sessions, and case-based learning to better recognize and manage atopic dermatitis (AD) across diverse skin tones.

4 experts in this video

Panelists discuss how patients with darker skin tones often experience delayed diagnosis due to misidentification as fungal infections or other conditions, emphasizing the importance of shared decision-making and patient education about the immune-mediated nature of the disease.

Panelists discuss the critical role of effective follow-up and multidisciplinary care in managing hidradenitis suppurativa, emphasizing ongoing patient education, coordinated referrals, and personalized treatment plans to improve adherence and long-term outcomes.

Panelists discuss the challenges of biologic access in hidradenitis suppurativa due to utilization management policies like step therapy, emphasizing the need for patient education, strategic planning, and leveraging resources—including clinical trials—to improve timely treatment and outcomes.

4 experts in this video

Panelists discuss how health care professionals face educational gaps in understanding atopic dermatitis (AD) immunopathogenesis, with advanced practice providers (APPS) particularly needing additional training outside standard curricula to master biologic therapy selection.

Panelists discuss key factors influencing biologic selection for hidradenitis suppurativa, including efficacy, safety, comorbidities, and insurance challenges, highlighting the importance of a holistic, multidisciplinary approach to optimize treatment and navigate practical barriers.

Panelists discuss the importance of coordinated, personalized treatment strategies for hidradenitis suppurativa, highlighting early use of pharmacologic therapies—including biologics—and ongoing assessment to balance clinical effectiveness, patient quality of life, and financial considerations.

Panelists discuss the significant disparities in hidradenitis suppurativa diagnosis and care, emphasizing the impact of race, gender, geography, and socioeconomic status, and highlighting the need for culturally competent education, expanded access, and community engagement to promote earlier intervention and equitable outcomes.

Panelists discuss the vital role of multidisciplinary collaboration, provider education, and technology integration in improving early diagnosis and comprehensive management of hidradenitis suppurativa, highlighting how coordinated efforts across specialties—including pharmacists—can reduce delays, enhance equity, and optimize patient outcomes.

Latest Updated Articles



    Brand Logo

    259 Prospect Plains Rd, Bldg H
    Monroe, NJ 08831

    609-716-7777

    © 2025 MJH Life Sciences®

    All rights reserved.

    Secondary Brand Logo